Ann: Novogen Announces Outcome of Comprehensive Science Review, page-58

Excuse the negativity, but I really am very disappointed and can't find many positives. Some are hoping that the new CEO will come in and change things around, but let's all be realistic:

1. A good CEO is likely to be very expensive. Now, do we really want such a CEO given the funding constraints? And do we need to pay a CEO multiples of what GK was paid to do possibly less?

2. In any case, why on earth would a high calibre CEO want the role at NRT, a small biotech with clear history of the board over-ruling the CEO? This could be a career ending role. Honestly, despite the claims of high calibre candidates, only people I can see applying are those who may have already retired or about to retire, since these people don't have to think about the next role.

There, I feel better now...